The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "Tofacitinib"

Search results for: Tofacitinib

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

August 29, 2017 • By Reuters Staff

NEW YORK (Reuters Health)—Tofacitinib begun two to three weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella zoster virus (VZV) immunity, researchers report. Patients with rheumatoid arthritis (RA) are about twice as likely as healthy adults to develop herpes zoster, or shingles, and the… [Read More]

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis & Rheumatology, shingles, Tofacitinib, vaccine, varicella zoster virus

FDA Committee Recommends Tofacitinib Approval

August 22, 2017 • By Michele B. Kaufman, PharmD, BCGP

The FDA Arthritis Advisory Committee voted 10 to 1 to recommend approval of tofacitinib to treat psoriatic arthritis…... [Read More]

Filed Under: Drug Updates Tagged With: Bimekizumab, FDA, Food and Drug Administration, Psoriasis, Psoriatic Arthritis, Tofacitinib

Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

July 13, 2017 • By Thomas R. Collins

Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: EULAR 2017

Tofacitinib Treatment May Improve Nail Psoriasis

April 24, 2017 • By Rita Buckley

NEW YORK (Reuters Health)—The oral Janus kinase (JAK) inhibitor tofacitinib appears to improve moderate to severe nail psoriasis, according to a new study. “Nails are hard to treat in psoriasis and we need better treatments,” says Dr. Luis Garza, a dermatologist at Johns Hopkins School of Medicine in Baltimore, who was not involved in the research…. [Read More]

Filed Under: Conditions, Scleroderma Tagged With: nails, plaque psoriasis, Psoriasis, Psoriatic Arthritis, Tofacitinib

The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA

December 20, 2016 • By Michele B. Kaufman, PharmD, BCGP

In a recent study, patients with psoriatic arthritis taking tofacitinib had a decrease in disease activity compared with placebo…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: disease-modifying antirheumatic drug, DMARD, Janus Kinase Inhibitors, Psoriatic Arthritis, Tofacitinib

Many Patients Discontinue Tofacitinib by Year 1; Fasinumab Promising for Pain

November 2, 2016 • By Michele B. Kaufman, PharmD, BCGP

A recent analysis found that about 10% of RA patients taking tofacitinib do not follow recommended guidelines and more than half stop treatment by one year…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: fasinumab, FDA, Food and Drug Administration, Nerve growth factor (NGF), osteoarthritis (OA), Pain, Tofacitinib, treatment guidelines

Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments

May 4, 2016 • By Michele B. Kaufman, PharmD, BCGP

A recent Phase 3 study found tofacitinib safe and effective for treating psoriatic arthritis at both 5 mg and 10 mg doses compared with placebo. And the FDA has added label warnings to saxagliptin and alogliptin for an increased risk of heart failure in individuals taking the drugs, particularly in those with heart and kidney disease…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, alogliptin, diabetes, FDA, Food and Drug Administration, Psoriatic Arthritis, saxagliptin, Tofacitinib

The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk

March 9, 2016 • By Michele B. Kaufman, PharmD, BCGP

The ACR has continued its advocacy to ensure the safe adoption of biosimilars in the U.S., most recently addressing an FDA public hearing. Also, the FDA has approved tofacitinib for RA, and a clinical trial of romosozumab for patients with osteoporosis met its primary endpoint…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: American College of Rheumatology, Biosimilars, FDA, Food and Drug Administration, infliximab, romosozumab, Tofacitinib, tofacitinib citrate

Tofacitinib Shows Ongoing Action Against Plaque Psoriasis

March 3, 2016 • By David Douglas

NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) shows long-term efficacy against chronic plaque psoriasis, according to findings from two randomized studies and an extension trial. The outcome, Dr. Svitlana Tatulych told Reuters Health by email, “demonstrated that oral tofacitinib, at both the 10 mg and 5 mg twice-daily doses, provided sustained… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Janus Kinase Inhibitors, plaque psoriasis, Tofacitinib

Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise

March 2, 2016 • By Michele B. Kaufman, PharmD, BCGP

Tofacitinib has been released from the FDA’s risk evaluation and mitigation strategy requirement. The FDA is also reviewing a biologics license application for ABP-501, an adalimumab biosimilar. And CHS-0214, a proposed etanercept biosimilar, has met its primary endpoint at Week 24 in an ongoing 52-week study…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, etanercept, FDA, Food and Drug Administration, Tofacitinib

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 13
  • Next Page »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.